<DOC>
	<DOCNO>NCT01155583</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , azacitidine dexamethasone , work different way stop growth cancer cell either kill cell stop dividing . Biological therapy , lenalidomide , may stimulate immune system different way stop cancer cell grow . Giving azacitidine together lenalidomide dexamethasone may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose azacitidine give together lenalidomide low-dose dexamethasone treat patient relapsed refractory multiple myeloma .</brief_summary>
	<brief_title>Low-Dose Azacitidine , Lenalidomide , Low-Dose Dexamethasone Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : Define high tolerate low dose ( HTLD ) safety azacitidine give low increase dose 50mg/m2 twice week concurrently GFR-adjusted lenalidomide low dose dexamethasone patient relapse refractory multiple myeloma . SECONDARY OBJECTIVES : - Response accord international response criterion ( ≥PR ) clinical benefit response ( ≥minor response accord adapt EBMT criterion ) - Correlate response plasma activity azacitidine inactivate enzyme cytidine deaminase ( CDA ) - Progression-free survival overall survival - Peripheral blood hematopoietic progenitor ( CD34+ ) yield time neutrophil platelet recovery patient undergo autologous stem cell transplantation - Promoter demethylation gene reactivation myeloma cell hematopoietic progenitor treat HTLD / HTLD-CKD level cycle 1 - Changes global gene expression myeloma cell treat HTLD / HTLD-CKD level cycle 1 OUTLINE : This phase I , dose-escalation study azacitidine follow phase II study . Patients receive azacitidine subcutaneously twice weekly oral dexamethasone weekly start day 1 . Patients also receive oral lenalidomide daily day 1-21 . Treatment repeat every 28 day 6 course . Patients continue receive lenalidomide maintenance therapy . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 3 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Understand voluntarily sign informed consent form Able adhere study visit schedule protocol requirement Refractory relapse multiple myeloma Measurable disease define least one following : Serum mspike ≥ 1g/dL , urine mspike ≥ 200mg/24hrs , serum free light chain ≥ 100mg/L ( provide kappa/lambda ratio abnormal ) , bone marrow plasma cell ≥ 30 % Previous therapy IMiD™ compound ( thalidomide , lenalidomide , pomalidomide ) , proteasome inhibitor ( bortezomib , carfilzomib ) , corticosteroid must discontinue least 14 day entry onto study . Previous cytotoxic chemotherapy ( e.g . alkylating chemotherapy , anthracyclines , vinca alkaloid ) , radiation therapy pelvis , experimental therapy carfilzomib pomalidomide must discontinue least 28 day prior entry onto study . ECOG performance status ≤ 2 study entry . Laboratory test result within range : Absolute neutrophil count ≥ 1,500 /mm³ Platelet count ≥ 75,000/mm³ Calculated creatinine clearance ( CockroftGault ) ≥ 30ml/min . Total bilirubin ≤ 1.5 x ULN Serum glutamicoxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) serum glutamicpyruvic transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) level ≤2 x ULN All study participant must register mandatory RevAssist® program , willing able comply requirement RevAssist® . Females childbearing potential ( FCBP ) must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 10 14 day prior within 24 hour prescribe lenalidomide ( prescription must fill within 7 day ) must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 28 day start take lenalidomide . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact FCBP even successful vasectomy . Able take aspirin ( 81 325 mg ) daily prophylactic anticoagulation ( patient intolerant ASA may use warfarin low molecular weight heparin ) additional risk factor VTE myeloma diagnosis accord IMW guideline Able take low molecular weight heparin warfarin ≥ 1 additional risk factor VTE accord IMW guideline Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form Pregnant breast feeding female ( Lactating female must agree breast feed take lenalidomide azacitidine ) Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study Use experimental drug therapy carfilzomib pomalidomide within 28 day treatment start protocol . Neuropathy &gt; Grade 2 Known hypersensitivity thalidomide , lenalidomide , azacitidine , mannitol The development erythema nodosum characterize desquamate rash take thalidomide lenalidomide drug Concurrent use anticancer agent treatment , concurrent radiation pelvis . Palliative radiation area outside pelvis allow Previous inability tolerate fulldose lenalidomide , adjust creatinine clearance ( CrCl ) accord CockroftGault time previous lenalidomide treatment ( 25mg day 121 every 28 day CrCl &gt; 60ml/min , 10mg lenalidomide d121 every 28 day CrCl &lt; 60mL/min &gt; 30mL/min , lenalidomide 15mg every 48 h d121 every 28 day CrCl &lt; 30mL/min require dialysis , lenalidomide 5mg daily , day 121 every 28 day CrCl &lt; 30mL/min require dialysis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>